Rhenman & Partners Asset Management Ab Tg Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $766 Million
- Q2 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 115,000 shares of TGTX stock, worth $3.89 Million. This represents 0.54% of its overall portfolio holdings.
Number of Shares
115,000
Previous 177,500
35.21%
Holding current value
$3.89 Million
Previous $7 Million
40.87%
% of portfolio
0.54%
Previous 0.83%
Shares
9 transactions
Others Institutions Holding TGTX
# of Institutions
407Shares Held
91.5MCall Options Held
2.28MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA15.8MShares$535 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$385 Million0.0% of portfolio
-
State Street Corp Boston, MA7.62MShares$258 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.49MShares$118 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY3.05MShares$103 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.91B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...